{"entity":{"id":"paper-srikanthan-pcodr-time-to-funding-curr-oncol-2017","kind":"paper","name":"Impact of the pan-Canadian Oncology Drug Review on provincial concordance and time to funding","aka":[],"tldr":"After Canada created a single national review of cancer drugs in 2011, provinces agreed more often on what to fund and the median time from licence to funding fell from 522 to 393 days.","summary":"A retrospective review used Health Canada's Drug Product Database to identify new cancer drug indications between January 2003 and May 2014 and provincial formularies for funding dates and decisions to the end of 2014, in nine provinces (all except Quebec), covering 88 indications for 51 drugs. Linear and quantile regression compared time to decision before and after the pan-Canadian Oncology Drug Review began, and kappa-type statistics measured agreement between provinces.\n\nInterprovincial concordance in funding decisions rose significantly (Brennan-Prediger coefficient 0.54 before against 0.78 after, p = 0.002), and the median time from Notice of Compliance to funding fell from 522 to 393 days (p < 0.001).","asOf":"2026-11-03","links":[{"label":"Curr Oncol 2017","url":"https://doi.org/10.3747/co.24.3648"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/29089796/"}],"tags":[],"related":[],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["cda-amc"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":["current-oncology-mdpi"],"dependsOn":[],"notes":[],"journal":"Current Oncology","year":2017,"doi":"10.3747/co.24.3648","pmid":"29089796","authors":"Srikanthan A, Mai H, Penner N, et al.","paperType":"observational","findings":["Median time from Health Canada licence to provincial funding fell from 522 to 393 days after pCODR began (p < 0.001).","Agreement between provinces on funding decisions rose from 0.54 to 0.78 (Brennan-Prediger coefficient, p = 0.002).","88 indications for 51 cancer drugs, nine provinces, Quebec excluded."],"whatItMeans":"A single national review made funding of cancer drugs faster and more alike across provinces, though it still took more than a year from licence to funding.","caveats":["Quebec was not included.","Two provinces lacked data for all 88 indications."]},"route":"/key-papers/paper-srikanthan-pcodr-time-to-funding-curr-oncol-2017/","neighbours":{"institution":[{"id":"cda-amc","kind":"institution","name":"Canada's Drug Agency (CDA-AMC)","route":"/institutions/cda-amc/"}],"journal":[{"id":"current-oncology-mdpi","kind":"journal","name":"Current oncology","route":"/journals/current-oncology-mdpi/"}]}}